Orteronel

N/A

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameOrteronel
Drug Alias NameOrteronelum奥特罗奈奥特奈TAK-700
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSteroid 17-alpha-hydroxylase inhibitors
TargetsSteroid 17-alpha-hydroxylase
Therapy Area/IndicationsMetastatic breast cancerHormone-Resistant Prostate NeoplasmsProstatic Neoplasms, Castration-Resistant +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[47] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPending
Originator CompaniesTakeda Pharmaceutical Co LtdMillennium Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteMillennium Pharmaceuticals Inc
Inactive CompaniesAlmac Clinical Services AudubonUniversity Of Southern CaliforniaUniversity Of Wisconsin-Madison +[7] 
Active IndicationsProstatic Neoplasms
Inactive IndicationsMetastatic breast cancerHormone-Resistant Prostate NeoplasmsProstatic Neoplasms, Castration-Resistant +[6] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG